BSECompany Update15h ago · 18 Nov 2026, 05:01 pm

Please find enclosed intimation of the exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited.

Piramal Pharma Ltd · 543635

✦ AI SummaryM&A

Piramal Pharma Ltd has exercised its call option to acquire the remaining 26% equity stake in Yapan Bio Private Ltd, a subsidiary, from existing shareholders. The final terms of the acquisition, including the consideration and effective date of transfer, are yet to be finalized. Upon completion, Yapan will become a wholly-owned subsidiary of Piramal Pharma Ltd.

Analysis Scores

Earnings Impact5/10
Growth Catalyst8/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Piramal Pharma Ltd - 543635 - Exercise Of Call Option To Acquire The Balance 26% Equity Stake In Yapan Bio Private Limited.

Attachments (1)

📄

db518f27-a966-4cb9-bd87-f7d3b0ff9918.pdf

pdf

Download →
View document text
18th November, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (‘SEBI Listing Regulations’) – exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Administrative Committee of the Board of Directors of Piramal Pharma Limited (‘the Company’), acting under the authority delegated by the Board, has approved the exercise of the Company's call option to acquire the balance 26% equity stake in Yapan Bio Private Limited (‘Yapan’), a subsidiary of the Company, from its existing shareholders (‘the Proposed Transaction’). Consequent to the exercise of the call option, the Company is engaged in discussions with the shareholders of Yapan in relation to matters necessary for consummation of the Proposed Transaction. The final terms of the acquisition, including the acquisition consideration and the effective date of transfer of shares, are yet to be finalized. The Company will make appropriate disclosures including the details as required under Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Securities Exchange of Board of India Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated January 30, 2026, upon execution of definitive documentation and completion of the Proposed Transaction. Yapan is a Contract Development and Manufacturing Organization that specializes in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics. Upon completion of the proposed transaction the Company’s shareholding in Yapan is expected to increase from the existing 74% to 100%, and Yapan will become a wholly owned subsidiary of the Company. Kindly take the above on record. Thank you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com